Cardiovascular effects of Etanercept in patients with psoriatic arthritis: Evidence from the cardiovascular risk in rheumatic diseases database

Expert Opinion on Drug Safety

Volumn 14, Issue 12, 2015, Pages 1905-1913

  Di Minno, Matteo Nicola Dario ^a   Iervolino, Salvatore ^b   Zincarelli, Carmela ^b   Lupoli, Roberta ^c   Ambrosino, Pasquale ^c   Pizzicato, Paolo ^c   Di Minno, Alessandro ^a   Pappone, Nicola ^b   Peluso, Rosario ^c  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cardiovascular risk factors; Etanercept; psoriatic arthritis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADHESION; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTERY THROMBOSIS; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; CAROTID ARTERY BIFURCATION; CAROTID ATHEROSCLEROSIS; DATA BASE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE; MINIMAL RESIDUAL DISEASE; PLATELET REACTIVITY; PRIMARY HEMOSTASIS; PSORIATIC ARTHRITIS; REVIEW; RISK REDUCTION; SECONDARY HEMOSTASIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; VEIN THROMBOSIS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; COMPLICATION; PATHOLOGY; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; ETANERCEPT; HUMANS; INFLAMMATION; RISK FACTORS;

EID: 84951905573     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1111870     Document Type: Review

References (66)

1. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673
2. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14-7
3. Peluso R, Iervolino S, Vitiello M, et al. Extra-Articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015 Apr;34(4):745-753
4. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison. Arthritis Care Res (Hoboken). 2011;63:1729-1735
5. Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: A retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015 May; 29(5):955-963
6. Di Minno MN, Iervolino S, Lupoli R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012;38:497-505
7. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868-1872
8. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: A systematic literature review. J Eur Acad Dermatol Venereol. 2013;27:12-29
9. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68:1131-1135
10. Jamnitski A, Visman IM, Peters MJ, et al. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis. 2011;70:875-876
11. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis-A singlecenter study from the UK. J Rheumatol. 2010;37:2141-2144
12. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247-1250
13. Mok CC, Ko GT, Ho LY, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63:195-202
14. Di Minno MN, Tremoli E, Coppola A, et al. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost. 2010;103:942-961
15. Slot O. Changes in plasma homocysteine in arthritis patients starting treatment with low dose methotrexate subsequently supplemented with folic acid. Scand J Rheumatol. 2001;30:305-307
16. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003
17. Wilson PW, DAgostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847
18. Chung CP, Oeser A, Avalos I, et al. Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2006;8:R186
19. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331
20. Di Minno MN, Iervolino S, Peluso R, et al. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol. 2012;39:334-336
21. Di Minno MN, Iervolino S, Peluso R, et al. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis: effect of different treatments. J Rheumatol. 2014;41:714-722
22. Di Minno MN, Iervolino S, Peluso R, et al. Carotid intima-media thickness in psoriatic arthritis. differences between tumor necrosis factor-α (TNF-α)-blockers and traditional disease modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31:705-712
23. Di Minno MN, Guida A, Camera M, et al. Overcoming limitations of current antiplatelet drugs. A concerted effort for more profitable strategies of intervention. Ann Med. 2011;43:531-544
24. Bray PF. Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am. 2007;21:633-645
25. Loffredo S, Ayala F, Marone GC, et al. Immunopathogenesis of psoriasis and psoriatic arthritis and pharmacological perspectives. Reumatismo. 2007;59:28-39
26. Barrett NE, Holbrook L, Jones S, et al. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008;154:918-939
27. Libby P, Ridker PM, Hansson GK. Leducq transatlantic network on atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-2138
28. Brambilla M, Parolari A, Camera M, et al. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost. 2010;103:516-524
29. Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005;106:2723-2729
30. Pappone N, Di Minno MN, Iervolino S, et al. The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis. Rheumatol Int. 2015
31. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum. 2002;46:2268-2279
32. Di Minno MN, Iervolino S, Peluso R, et al. TNF-α blockers and carotid intimamedia thickness: An emerging issue in the treatment of psoriatic arthritis. Intern Emerg Med. 2012;7:S97-98
33. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-Alpha blockade. J Autoimmun. 2008;31:175-179
34. Di Minno MN, Iervolino S, Peluso R, et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis on TNF-α blockers. J Rheumatol. 2012;39:1042-1046
35. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36:729-740
36. Agirbasli M, Inanc N, BaykanOA, et al. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol. 2006;24:580-583
37. Hou B, Eren M, Painter CA, et al. Tumor necrosis factor α activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappa B. J Biol Chemistry. 2004;279:18127-18136
38. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 2001;40:640-644
39. Cugno M, Ingegnoli F, Gualtierotti R, et al. Potential effect of anti-tumour necrosis factor-Alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol. 2010;8:285-292
40. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5:132-142
41. Di Minno MN, Pezzullo S, Palmieri V, et al. Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. Thromb Res. 2010;126:e434-438
42. Ingegnoli F, Fantini F, Griffini S, et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:254-257
43. Peluso R, Cafaro G, Di Minno A, et al. Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies. Clin Rheumatol. 2013;32:743-753
44. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther. 2002;16:341-351
45. De Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109:III33-III38
46. OLeary DH, Polak JF, Kronmal RA, et al. Carotid-Artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14-22
47. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146:483-494
48. Belcaro G, Nicolaides AN, Ramaswami G, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: A 10-year follow-up study (the CAFES-CAVE study. Atherosclerosis. 2011;156:379-387
49. Kimhi O, Caspi D, Bornstein NM, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203-209
50. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:287-293
51. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, et al. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57:1074-1080
52. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112:3337-3347
53. Di Minno MN, Ambrosino P, Lupoli R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: A metaanalysis of literature studies. Ann Med. 2015;47:346-353
54. Van Den Oever IA, Van Sijl AM, Nurmohamed MT. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis. 2013;5:166-181
55. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70:8-14
56. Jacobsson LT, Turesson C, Glfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213-1218
57. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905-2912
58. Di Minno MN, Ambrosino P, Peluso R, et al. Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: A meta-Analysis of prospective studies. Ann Med. 2014;46:73-83
59. Amaya-Amaya J, Sarmiento-Monroy JC, Mantilla RD, et al. Novel risk factors for cardiovascular disease in rheumatoid arthritis. Immunol Res. 2013;56:267-286
60. Urruticoechea-Arana A, Martn-Martnez MA, Castaeda S, et al. Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. Arthritis Res Ther. 2015;17:211
61. Reynolds J, Ray D, Alexander MY, et al. Role of vitamin D in endothelial function and endothelial repair in clinically stable systemic lupus erythematosus. Lancet. 2015;385:S83
62. Yin K, You Y, Swier V, et al. Vitamin D protects against atherosclerosis via regulation of cholesterol efflux and macrophage polarization in hypercholesterolemic swine. Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2432-2442
63. Hollan I, Dessein PH, Ronda N, et al. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;14:952-969
64. Ambrosino P, Tasso M, Lupoli R, et al. Non-invasive assessment of arterial stiffness in patients with rheumatoid arthritis: A systematic review and meta-Analysis of literature studies. Ann Med. 2015 Sep; 47(6):457-467
65. Ambrosino P, Lupoli R, Di Minno A, et al. Markers of cardiovascular risk in patients with antiphospholipid syndrome: A meta-Analysis of literature studies. Ann Med. 2014;46:693-702
66. Ambrosino P, Lupoli R, Di Minno A, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-Analysis of literature studies. Thromb Haemost. 2015;113:916-930.